KENNEDY CAPITAL MANAGEMENT LLC

Position in NAMS — NewAmsterdam Pharma Co N.V.

CIK 884589 ST LOUIS, MO

Position in NAMS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$14,280,364

+$1,204,536 QoQ

Shares Held

421,374

+3.2% QoQ

Ownership

0.353%

of shares outstanding

% of Portfolio

0.26%

of 13F equity value

Holder Rank

#44

of 197 holders

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 94% Shared 0% None 6%

Healthcare · as of Jun 30, 2026

KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. NAMS ranks #8 (3.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	HALO	Halozyme Therapeutics, Inc.	544,994	$42,656,680
2	RYTM	Rhythm Pharmaceuticals, Inc.	193,215	$21,452,661
3	NRIX	Nurix Therapeutics, Inc.	724,508	$17,576,564
4	CORT	Corcept Therapeutics Inc	201,979	$17,562,074
5	PTGX	Protagonist Therapeutics, Inc	134,019	$16,428,049
6	MGTX	MeiraGTx Holdings plc	1,105,421	$14,934,237
7	ADMA	Adma Biologics, Inc.	1,755,152	$14,690,622
8	NAMS	NewAmsterdam Pharma Co N.V. This page	421,374	$14,280,364

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$14,280,364	421,374	+3.2%	Shares	Sole	2026-08-14
2026-03-31	$13,075,828	408,492	+136.2%	Shares	Sole	2026-05-13
2025-12-31	$6,066,419	172,931	+17.9%	Shares	Sole	2026-02-13
2025-09-30	$4,172,574	146,715	+972.9%	Shares	Sole	2025-11-13
2025-06-30	$247,654	13,675	+72.1%	Shares	Sole	2025-08-13
2024-12-31	$204,186	7,945	-43.4%	Shares	Sole	2025-02-13
2024-09-30	$233,163	14,046	+18.5%	Shares	Sole	2024-11-14
2024-06-30	$227,696	11,853	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.